Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Sirin Gandhi, Dejan Jakimovski, Rahil Ahmed, David Hojnacki, Channa Kolb, Bianca Weinstock-Guttman & Robert Zivadinov. (2016) Use of natalizumab in multiple sclerosis: current perspectives. Expert Opinion on Biological Therapy 16:9, pages 1151-1162.
Read now
Read now
Articles from other publishers (17)
Toshihiko SugiuraAyatoshi AndouYoshiyuki HosoiTetsuya Koyama. (2023) Pharmacological and Clinical data of oral alpha 4 integrin antagonist, Carotegrast methyl, CAROGRA<sup>®</sup>経口α4インテグリン阻害薬カロテグラストメチル（カログラ<sup>®</sup>錠120 mg）の薬理学的特徴と臨床試験成績. Folia Pharmacologica Japonica 158:2, pages 203-210.
Crossref
Crossref
Wei Zou & Michael J. Imperiale. (2021) Biology of Polyomavirus miRNA. Frontiers in Microbiology 12.
Crossref
Crossref
Tjalf Ziemssen, Michael Lang, Björn Tackenberg, Stephan Schmidt, Holger Albrecht, Luisa Klotz, Judith Haas, Christoph Lassek, Christian Cornelissen & Benjamin Ettle. (2020) Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab. Multiple Sclerosis and Related Disorders 39, pages 101893.
Crossref
Crossref
Hiroyuki Fukase, Toshifumi Kajioka, Ichiro Oikawa, Naoki Ikeda & Hidetoshi Furuie. (2020) AJM300, a novel oral antagonist of α4‐integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects. British Journal of Clinical Pharmacology 86:3, pages 591-600.
Crossref
Crossref
Malin Nilsson, Jørgen Rungby, Nathan Lassota, Andreas D. Jørgensen, Rikke Ibsen & Jakob Kjellberg. (2018) No Impact of Pre-existing Cardiovascular Disease on Prescribing Patterns of Sulphonylureas in Denmark - A Registry-based Nationwide Study. Basic & Clinical Pharmacology & Toxicology 122:6, pages 606-611.
Crossref
Crossref
JASNA JANCIC, BLAŽO NIKOLIC, NIKOLA IVANCEVIC, BORIS HENCIC & JANKO SAMARDŽIC. 2017. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis
39
52
.
Óscar Fernández. (2017) Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?. Multiple Sclerosis and Related Disorders 17, pages 75-83.
Crossref
Crossref
José Eustasio Meca-Lallana, Ester Carreón-Guarnizo, Rocío Hernández-Clares, Estefanía García-Molina, José Díaz-Pérez, Adelaida Leon-Hernández, Joaquín Zamarro-Parra & José Javier Martín-Fernández. (2017) Clinical and radiological control of highly active relapsing-remitting multiple sclerosis with first-line natalizumab. Neurodegenerative Disease Management 7:3, pages 175-181.
Crossref
Crossref
Diana L Vargas & William R Tyor. (2023) Update on Disease-Modifying Therapies for Multiple Sclerosis. Journal of Investigative Medicine 65:5, pages 883-891.
Crossref
Crossref
Julia Krämer, Jan-Gerd Tenberge, Ingo Kleiter, Wolfgang Gaissmaier, Tobias Ruck, Christoph Heesen & Sven G. Meuth. (2017) Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?. PLOS ONE 12:4, pages e0174858.
Crossref
Crossref
Elena Uleri, Gabriele Ibba, Claudia Piu, Maurizio Caocci, Stefania Leoni, Giannina Arru, Caterina Serra, GianPietro Sechi & Antonina Dolei. (2016) JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab. Journal of NeuroVirology 23:2, pages 226-238.
Crossref
Crossref
Pavel Polák. (2017) Progresivní multifokální leukoencefalopatie - editorial. Vnitřní lékařství 63:1, pages 22-23.
Crossref
Crossref
Jasna Jancic, Blazo Nikolic, Nikola Ivancevic, Vesna Djuric, Ivan Zaletel, Dejan Stevanovic, Sasa Peric, John N. van den Anker & Janko Samardzic. (2016) Multiple Sclerosis in Pediatrics: Current Concepts and Treatment Options. Neurology and Therapy 5:2, pages 131-143.
Crossref
Crossref
Klaus Rose & Thomas Müller. (2016) Children with multiple sclerosis should not become therapeutic hostages. Therapeutic Advances in Neurological Disorders 9:5, pages 389-395.
Crossref
Crossref
Francesca Rossi, Xiuhong Li, Lisa Jacobson, Andrew J. Levine, Yue Chen, Frank J. Palella, Joseph Margolick & Raphael Viscidi. (2015) BK virus capsid antibodies are associated with protection against subsequent development of PML in HIV-infected patients. Virology 485, pages 467-472.
Crossref
Crossref
Yasser El Miedany. (2015) MABS: targeted therapy tailored to the patient's need. British Journal of Nursing 24:Sup16a, pages S4-S13.
Crossref
Crossref
Lilyana Amezcua, Mark J. Morrow & Guy V. Jirawuthiworavong. (2015) Multiple sclerosis. Current Opinion in Ophthalmology, pages 1.
Crossref
Crossref